jRCT2080221605未知1 期
A Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors.
试验速览
- 阶段
- 1 期
- 入组人数
- 85
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Open-label, single-center, phase I study
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- All
入选标准
- •Signed, written informed consent.
- •Histologically or cytologically confirmed solid tumor.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
排除标准
- •Investigational drug therapy within 28 days prior to enrollment.
- •Radiotherapy within 21 days prior to enrollment.
- •Received extensive prior radiotherapy on more than 30% of bone marrow.
- •Females who are pregnant or breastfeeding.
- •Serious complications.
结局指标
主要结局
-
Safety CTCAE (ver.4.03)
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Phase I Study of TAS-115 in Patients with Advanced Solid TumorsjRCT2080222284Taiho Pharmaceutical Co., Ltd.90
已完成
1 期
Phase I Study of TAS-116 in Patients with Advanced Solid TumorsjRCT2080222394Taiho Pharmaceutical Co., Ltd.150
已完成
1 期
Phase I Study of TAS-120 in Patients with Advanced Solid TumorsjRCT2080222501Taiho Pharmaceutical Co., Ltd.142
已完成
2 期
Phase II study of TAS-102 in patients with advanced gastric cancer after progression on 1 or 2 prior systemic chemotherapyadvanced gastric cancerJPRN-UMIN000007421ational Cancer Center Hospital East28
进行中（未招募）
1 期
A Phase 2 Study of TAS-117 in Patients with Advanced Solid Tumors Harboring Germline PTEN Inactivating MutationsAdvanced Solid Tumors Harboring Germline PTEN Inactivating MutationsMedDRA version: 23.0Level: PTClassification code 10071986Term: PTEN gene mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-004770-22-ATTaiho Oncology, Inc.100